ストックスクリーナーアプリを入手
2.67
0.94%
0.02
前日終値:
$2.65
開ける：
$2.66
24時間の取引高:
3,343
Relative Volume:
0.04
時価総額：
$8.07M
収益：
$3.91M
当期純損益:
$-11.65M
株価収益率:
-0.2167
EPS:
-12.3212
ネットキャッシュフロー:
$-11.51M
1週間 パフォーマンス:
-3.43%
1か月 パフォーマンス:
+47.79%
6か月 パフォーマンス:
-41.34%
1年 パフォーマンス:
-81.80%
1日の値動き範囲:
$2.57
$2.70
1週間の範囲:
$2.57
$3.49
52週間の値動き範囲:
$1.52
$24.90
Intelligent Bio Solutions Inc Stock (INBS) Company Profile
Compare INBS vs ABT, SYK, MDT, BSX, EW
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
INBS
Intelligent Bio Solutions Inc
|
2.675 | 8.06M | 3.91M | -11.65M | -11.51M | -12.32 |
ABT
Abbott Laboratories
|
115.73 | 198.01B | 46.59B | 5.41B | 7.38B | 3.0938 |
SYK
Stryker Corp
|
329.36 | 130.41B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
92.61 | 120.48B | 36.36B | 4.84B | 5.43B | 3.7261 |
BSX
Boston Scientific Corp
|
49.87 | 75.37B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
89.91 | 53.19B | 6.30B | 1.07B | 1.09B | 1.8406 |
Intelligent Bio Solutions Inc (INBS) 最新ニュース
Intelligent Bio Solutions completes clinical data collection for FDA 510(k) - scanx.trade
INBS Looks 0.4% Overvalued on GF Value™ - GuruFocus
Intelligent Bio Solutions Revenue Rises 38% to $4.2 Million in Fiscal 2026 - Moomoo
Intelligent Bio Solutions resolves all cybersecurity review items ahead of H2 2026 FDA filing - scanx.trade
Intelligent Bio Solutions revenue rises 38% to $4.2 million - grafa.com
BRIEF-Intelligent Bio Solutions Reports Fiscal 2026 Full-Year Revenue Growth Of 38% Year-Over-Year, Driven By Reader Installed Base And High-Margin Cartridge Growth - Bitget
Form 8K Intelligent Bio Solutions Inc For: 19 August By Investing.com - Investing.com Nigeria
Intelligent Bio Solutions Inc. Reports Earnings Results for the Full Year Ended June 30, 2026 - marketscreener.com
INBS FY26 Results: Revenue up 38% to $4.2M, margin expands to 48.6% - scanx.trade
Intelligent Bio Solutions Revenue Jumps 38% as Gross Margin Expands 778 Basis Points - Minichart
Intelligent Bio Solutions | 10-K: Annual report - Moomoo
Intelligent Bio Solutions Reports Fiscal 2026 Revenue Up 38% to $4.22M, Gross Margin 48.63% - TradingView
INBS: Revenue up 38% to $4.2M, gross margin 48.63%, FDA submission on track for late 2026 - TradingView
INTELLIGENT BIO SOLUTIONS INC. FY 2026: Revenue $4.22M, EPS $(8.44) — 10-K Summary - TradingView
Intelligent Bio Solutions Reports Fiscal 2026 Full-Year Revenue Growth Of 38% Year-Over-Year, Driven By Reader Installed Base And High-Margin Cartridge Growth - TradingView
Intelligent Bio (NASDAQ: INBS) warns on cash and survival - Stock Titan
Intelligent Bio Solutions grows to 502 customers as net loss widens to $12.5M - Stock Titan
Intelligent Bio Solutions (NASDAQ:INBS): Can Commercial Adoption Accelerate? - Kalkine Media
Intelligent Bio Solutions Shares Surge Monday: What's Driving the Action? - Benzinga
Intelligent Bio Solutions receives ISO 13485:2016 recertification - Investing.com
Intelligent Bio Solutions receives ISO 13485:2016 recertification By Investing.com - Investing.com Canada
Intelligent Bio Solutions Strengthens Quality Management Credentials with ISO Recertification - The Manila Times
A Fingerprint Drug Test Aligns With the FDA's New Regulation—What's Next? - Stock Titan
What Should Readers Watch in Intelligent Bio Solutions (NASDAQ:INBS) as Diagnostic Adoption Comes Into Focus? - Kalkine Media
INBS Drops 7.67% to $2.77 as Intelligent Bio Solutions Approaches Key SupportNews Sentiment - Vinanet
Intelligent Bio Solutions (INBS) gets 5.91% ownership update from Armistice Capital - Stock Titan
Intelligent Bio Solutions (INBS) Surges 15.35% to $2.93 — Testing Key Resistance at $3.08Skew Index - Vinanet
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Form 8K Intelligent Bio Solutions Inc For: 11 August By Investing.com - Investing.com Canada
Intelligent Bio Solutions Advances FDA Fingerprinting Drug Study - TipRanks
Intelligent Bio Solutions completes multi-site study, targets FDA 510(k) submission in H2 2026 - TradingView
Intelligent Bio Solutions Inc. (INBS) stock price, news, quote and history - Yahoo Finance Singapore
INBS Looks 48.6% Undervalued on GF Value™ but Faces Challenges - GuruFocus
Intelligent Bio Solutions completes FDA clinical study program By Investing.com - Investing.com Australia
Intelligent Bio Solutions completes FDA clinical study program - Investing.com
Intelligent Bio Solutions Announces Completion of Method Comparison Study for the Intelligent Fingerprinting Drug Screening System - The Manila Times
Intelligent Bio Solutions Completes Method Comparison Study for the Intelligent Fingerprinting Drug Screening System - marketscreener.com
INBS Stock Reverses Early Gains After First Shipment of Drug Screening Readers Under Syrma Johari MedTech Partnership - Stocktwits
Intelligent Bio Solutions (INBS) Slips 1% as Shares Test Key Support at $1.86Equal Weight ETF - Vinanet
INBS Q1 2025 Earnings: Deeper-Than-Expected Loss Highlights Persistent Cost PressureMargin Expansion Trends - Vinanet
Intelligent Bio Solutions Inc (INBS) Stock News Today - TradingKey
Intelligent Bio Solutions Inc (INBS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
INBS Q4'26 Earnings: revenue estimate is 1.22M USD - TradingView
Intelligent Bio Solutions Completes Usability Study For Intelligent Fingerprinting Drug Screening System Supporting FDA 510(k) Submission - marketscreener.com
Intelligent Bio Solutions Advances Fingerprint Drug Screening Program - TipRanks
Intelligent Bio Solutions completes usability study for FDA filing - Investing.com
Intelligent Bio Solutions completes usability study for FDA filing By Investing.com - Investing.com India
Intelligent Bio Solutions Completes Usability Study for Fingerprinting Drug Screen; 510(k) on Track - TradingView
Intelligent Bio Solutions Completes Usability Study Supporting FDA 510(k) Submission - The Manila Times
15 Operators Used Intelligent Bio Solutions' Drug Test Without Lab Training - Stock Titan
Intelligent Bio Solutions Expands Share Count Through Equity Transactions - tipranks.com
Intelligent Bio Solutions Inc (INBS) 財務データ
収益
当期純利益
現金流量
EPS
0.32%
0.15%
大文字化:
|
ボリューム (24 時間):